Centralization of Epithelial Ovarian Cancer Care and Outcomes in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter observational study conducted in the Emilia-Romagna region of Italy. It analyzes both retrospective and prospective data from patients with epithelial ovarian cancer treated from 2018 to 2023, focusing on the impact of centralized care and COVID-19–related treatment changes on oncologic outcomes. The primary aim is to compare progression-free survival and overall survival across three periods: before centralization, during the pandemic peak, and during pandemic control. The study also notes shifts toward neoadjuvant chemotherapy, multidisciplinary evaluation, BRCA testing, and interval debulking surgery as part of the care pathways. No experimental interventions are being tested; the study observes real-world practices and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients aged between 18 and 99 years
* Histological and/or cytological diagnosis of epithelial ovarian cancer
* Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia
* Patients treated between January 1, 2018, and December 31, 2023
* Availability of clinical records and outcome data
* Signed informed consent where possible, in accordance with GDPR and Italian regulations

Exclusion Criteria:

* Patients without histological or cytological confirmation of epithelial ovarian cancer
* Incomplete or missing data for key clinical indicators
* Patients unable to provide informed consent and for whom recontact is not possible
* Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)

Where it's running

• Azienda Unità - Sanitaria locale di Modena - Ospedale Razzini Carpi
  Carpi, Modena, Italy Recruiting
• Azienda Unità - Sanitaria locale di Modena - Ospedale di Mirandola
  Mirandola, Modena, Italy Recruiting
• Azienda Unità - Sanitaria locale di Modena - Ospedale Civile Sassuolo
  Sassuolo, Modena, Italy Recruiting
• Azienda USL IRCCS di Reggio Emilia
  Reggio Emilia, Re, Italy Recruiting
• Azienda Ospedaliero - Universitario di Modena
  Modena, Italy Recruiting
• Azienda Unità - Sanitaria locale di Modena - Ospedale Pavullo nel Frignano
  Pavullo nel Frignano, Modena, Italy Not yet recruiting

Study contacts

• Principal investigator: Vincenzo Dario Mandato, MD — Azienda USL Reggio Emilia - IRCCS
• Study coordinator: Vincenzo Dario Mandato, MD - Principal Investigator
• Email: vincenzodario.mandato@ausl.re.it
• Phone: +39 0522 295467

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Whole-body metabolic activity as a predictor of chemotherapy response in epithelial ovarian cancer

  This study tests whether whole-body metabolic activity can predict how well epithelial ovarian cancer responds to chemotherapy.

  Recruiting University of Tennessee Graduate School of Medicine · Knoxville, Tennessee · NCT07764133

• [68Ga]BED003 PET imaging to see fibroblast activity in selected cancers

  This study tests a PET imaging agent, [68Ga]BED003, to see how well it detects tumors in colorectal, gastric, pancreatic, ovarian, and invasive lobular breast cancers.

  Recruiting at 5 sites Phase 2 Blue Earth Diagnostics · Bergamo, Lombardy and 5 other locations · NCT07702292

• Mo-Rez maintenance therapy in first-line ovarian cancer

  This study tests mocertatug rezetecan (Mo-Rez) alone or with bevacizumab to see if it helps people with newly diagnosed advanced ovarian cancer, compared with bevacizumab alone or no active treatment after initial chemotherapy.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Buenos Aires and 11 other locations · NCT07694427

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.